The degree of T-cell infiltration has been suggested as an important prognostic biomarker for colorectal cancer (CRC) patients, regardless of other clinical and/or pathological factors. In this study, we analyzed tumor-infiltrating lymphocyte (TIL) counts of CRC using Lunit SCOPE IO, an artificial intelligence (AI)-powered whole slide image (WSI) software analyzer. Our aim was to analyze the prognostic significance of AI-powered TIL analysis in CRC.
Lunit SCOPE IO was trained and validated with a 2.8 x 109 micrometer2 area and 5.9 x 106 TILs from 3,166 H&E Whole-Slide Images (WSI) of multiple cancer types, annotated by 52 board-certified pathologists. The Inflamed Score (IS) was defined as the proportion of all tumor-containing 1 mm2-size tiles within a WSI classified as being of the inflamed immune phenotype (high TIL density within cancer epithelium). H&E images, sequencing data and survival data of stage I-III CRC patients from The Cancer Genome Atlas (TCGA) were utilized for this analysis.
Stage I-III CRC samples (n = 461) with clinical data were analyzed. The median of IS was 8.56 (IQR 3.74-18.39). IS showed moderate positive correlations with CD8A (rs = 0.422, p < 0.001) and CD3G (rs = 0.377, p < 0.001) expression levels but weaker positive correlations with regulatory T cells (rs = 0.162, p < 0.001), TH1 (rs = 0.209, p < 0.001) or TH2 cell proportions (rs = 0.128, p = 0.006). The IS was higher in CMS1 group compared to CMS 2-4 groups (median 18.49 vs. 6.90, p < 0.001). No significant differences in IS was observed across TNM stages. The recurrence-free survival of the patients with IS higher than third quartile (>= 18.39) were significantly longer compared to the lower group (p = 0.034, HR 0.540, 95% CI 0.306-0.954). The same outcome was observed in cases with MSS tumors (p = 0.023, HR 0.380, 95% CI 0.165-0.877).
AI-powered analysis of WSI can provide prognostic information in stage I-III CRC patients. Further development of AI-powered TIL analysis including the spatial
C. Park1, Y. Lim2, S. Song2, S. Ahn2, J. Ryu2, H. Song2, M. Ma2, S. Park2, S. Pereira2, B.J. Aum2, S. Shin2, S. Cho2, K. Paeng2, D. Yoo2, W. Jung2, C. Ock2
1 Internal Medicine, Seoul National University Hospital, 03080 - Seoul/KR
2 Oncology Group, Lunit Inc., 06241 - Seoul/KR
Abstract: Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Reducing Domain Gap by Reducing Style Bias
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma.
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Abstract : Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Analyzer Reduces Inter-observer Variation in PD-L1 Tumor Proportion Score of Non-Small Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...
Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals immune-excluded phenotype is correlated with TGF-beta pathway related genomic aberrations
Observer Performance Study to Examine the Feasibility of the AI-powered PD-L1 Analyzer to Assist Pathologists’ Assessment of PD-L1 Expression Using Tumor Proportion Score in Non-Small Cell Lung Cancer
Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation
Artificial intelligence-powered whole-slide image analyzer reveals a distinctive distribution of tumor-infiltrating lymphocytes in neuroendocrine tumors and carcinomas
Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)
Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes
Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types
Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study
Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.